Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire:results from an observational cohort study in Dutch primary care by Blanker, Marco H et al.
  
 University of Groningen
Determining the minimal important differences in the International Prostate Symptom Score
and Overactive Bladder Questionnaire
Blanker, Marco H; Alma, Harma Johanna; Devji, Tahira Sakina; Roelofs, Marjan; Steffens,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Blanker, M. H., Alma, H. J., Devji, T. S., Roelofs, M., Steffens, M. G., & van der Worp, H. (2019).
Determining the minimal important differences in the International Prostate Symptom Score and Overactive
Bladder Questionnaire: results from an observational cohort study in Dutch primary care. BMJ Open, 9(12),
e032795. https://doi.org/10.1136/bmjopen-2019-032795
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 21-02-2020
1Blanker MH, et al. BMJ Open 2019;9:e032795. doi:10.1136/bmjopen-2019-032795
Open access 
Determining the minimal important 
differences in the International Prostate 
Symptom Score and Overactive Bladder 
Questionnaire: results from an 
observational cohort study in Dutch 
primary care
Marco H Blanker   ,1 Harma Johanna Alma,1,2 Tahira Sakina Devji   ,3 
Marjan Roelofs,1 Martijn G Steffens,4 Henk van der Worp   1
To cite: Blanker MH, Alma HJ, 
Devji TS, et al.  Determining 
the minimal important 
differences in the International 
Prostate Symptom Score 
and Overactive Bladder 
Questionnaire: results from an 
observational cohort study in 
Dutch primary care. BMJ Open 
2019;9:e032795. doi:10.1136/
bmjopen-2019-032795
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
032795).
Received 06 July 2019
Revised 25 November 2019
Accepted 04 December 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Marco H Blanker;  
 m. h. blanker@ umcg. nl
Original research
© Author(s) (or their 
employer(s)) 2019. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Objectives To determine the minimal important difference 
(MID) of the International Prostate Symptom Score (IPSS) 
and the Overactive Bladder Questionnaire short form 
(OAB- q SF) assessed in primary care among patients 
treated for lower urinary tract symptoms (LUTS).
Design Single- arm, open- label observational cohort study 
with a 6- week follow- up.
Setting Twenty- two pharmacies in the Netherlands.
Participants We enrolled Dutch men with uncomplicated 
LUTS who received a new alpha- blocker prescription from 
their general practitioner or urologist.
Primary and secondary outcomes The IPSS and OAB- q 
SF were completed before and after 6 weeks of therapy. 
At 6 weeks, men also completed the Patient Global 
Impression of Improvement (PGI- I). The mean change 
scores of the IPSS and OAB- q SF were calculated for each 
PGI- I outcome category, with the category ‘a little better’ 
used to determine the MID. The SE of measurement (SEM) 
was calculated for each questionnaire.
Results In total, 165 men completed follow- up. The MID 
was 5.2 points (95% CI 3.9 to 6.4; SEM 3.6) for the IPSS 
and 11.0 points (95% CI 7.1 to 14.9; SEM 9.7) for the 
OAB- q SF. For both questionnaires, CIs showed an overlap 
with the no- change categories. However, the MID for the 
IPSS was higher in men with severe baseline symptoms 
(7.1; 95% CI 5.3 to 9.0) than in men with moderate 
baseline symptoms (3.2; 95% CI 1.7 to 4.8).
Conclusion In this study, the MID for the IPSS was 
considerably higher than the MID of 3.1 reported in 
the only other study on this topic, but may be due to 
methodological differences. Interpretation of the MID 
for the OAB- q SF is hampered by the overlap with the 
SEM. Future studies are needed to confirm our results 
because correlations between the PGI- I and symptom 
questionnaires were suboptimal.
InTRODuCTIOn
Symptom severity is a key outcome for patients 
with lower urinary tract symptoms (LUTS) 
and is most often evaluated by direct patient 
inquiry, using patient- reported outcome 
measures (PROMs). Although the Interna-
tional Prostate Symptom Score (IPSS) is most 
often used for this purpose in both clinical 
trials and practice,1–5 it fails to capture prob-
lematic symptoms such as urinary inconti-
nence and urgency. Therefore, the Overactive 
Bladder Questionnaire (OAB- q) is increas-
ingly being used to evaluate the treatment 
of OAB,6 7 with the short form (ie, OAB- q 
SF) having the advantage of being less time 
consuming.8 Together, both of the IPSS and 
OAB- q SF capture the spectrum of outcomes 
that are important to patients, but it is diffi-
cult to interpret the effects of an intervention 
expressed as mean scores or change scores 
over time.
The minimal important difference (MID) 
has proven invaluable when interpreting 
Strengths and limitations of this study
 ► We assessed the minimal important difference (MID) 
of two frequently used questionnaires on lower uri-
nary tract symptoms.
 ► Given that many men are treated in primary care, 
MID values for this setting are particularly import-
ant to inform evidence- based decision- making 
and to facilitate interpretation of the International 
Prostate Symptom Score and Overactive Bladder 
Questionnaire short form.
 ► Notably, the sample size of this study was small, 
which resulted in very low numbers of men be-
ing included in the Patient Global Impression of 
Improvement category ‘very much better’ or ‘wors-
ening of symptoms’, and may clarify the small over-
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PROMs and could be of great value for both the IPSS and 
OAB- q SF.9 10 To date, the MID has only been reported for 
the IPSS in a study conducted in secondary care among 
participants of clinical trials.1 2 There has been no report 
of the MID for the OAB- q SF in any care setting. In coun-
tries like the Netherlands and the UK, most men with 
LUTS first visit their general practitioner(GP) to seek 
treatment. Given that setting may affect the MID, possibly 
because of differences in baseline symptom severity,9–11 
we feel that it is important to assess the MID in a primary 
care setting. To date the MID for secondary care settings 
has been applied in guidelines for primary care.3 5 It is 
unclear if applying the threshold for a clinically relevant 
outcome is appropriate. Men who receive treatment need 
to be aware of what can be expected. Knowledge about the 
MID in primary care will then provide invaluable data for 
interpreting treatment outcomes that may differ between 
primary and secondary care. In addition, evidence must 
be obtained from multiple studies to ensure that MID 
determinations are accurate.
In the current study, we aimed to determine the MIDs 
for both the IPSS and OAB- q SF in a patient cohort origi-
nating mainly from primary care.
MeThODS
Study design
We conducted a prospective cohort study between 
January 2016 and April 2018.12 Baseline data for the 
IPSS and OAB- q SF were compared with follow- up data 
after 6 weeks of treatment. At follow- up, participants also 
completed the Patient Global Impression of Improve-
ment (PGI- I) and we calculated the MID.
Participants
Adult men who visited a participating pharmacy in the 
north of the Netherlands were included if they received a 
new alpha- blocker prescription for uncomplicated LUTS 
from a GP or urologist. A prescription was defined as new 
if no alpha- blocker prescription had been given within the 
past year. The pharmacists checked if the alpha- blocker 
was indicated for LUTS and excluded men prescribed 
alpha- blockers for urinary tract stones or indwelling cath-
eters. All participants provided written informed consent.
Data collection
At baseline, before starting alpha- blocker therapy, all 
participants provided relevant descriptive data (eg, age, 
duration of LUTS in months or years and history of 
surgery for LUTS) and completed the Dutch versions 
of the IPSS and OAB- q SF. After 6 weeks, men who 
consented repeated the IPSS and OAB- q SF by postal invi-
tation. At this time, we asked participants to complete the 
PGI- I questionnaire.13 The period of 6 weeks was chosen 
as clinical effects of alpha- blockers take a few weeks to 
develop fully, but significant efficacy over placebo can 
occur within hours to days.4 14
Questionnaires
The IPSS questionnaire was originally validated as the 
American Urological Association Symptom Index for benign 
prostatic hyperplasia.1 It includes seven questions covering 
frequency, nocturia, weak urinary stream, hesitancy, inter-
mittence, incomplete emptying and urgency. Each ques-
tion has response options ranging from 0 to 5, with higher 
scores reflecting more severe symptoms. Total scores that 
may range from 0 (no symptoms) to 35 points (maximum 
score), and scores are often categorised as no/mild symp-
toms (0–7 points), moderate symptoms (8–19 points), 
or severe symptoms (≥20 points). The questionnaire was 
internally consistent (Cronbach’s alpha=0.86) and has 
excellent test–retest reliability (r=0.92).1 The MID for 
the IPSS is currently considered to be 3.1 points.2 The 
American Urological Association - Symptom Index (AUA- 
SI) has been internationally adopted and implemented 
worldwide under the name IPSS.
IPSS focuses on the concept of ‘benign prostatic hyper-
plasia’ as cause of male LUTS, which appeared to have a 
multifactorial origin. OAB is one of the alternative expla-
nations of LUTS. Although urgency (included in the 
IPSS) relates to OAB, OAB includes other symptoms as 
well, which are not included in the IPSS questionnaire. 
Therefore, Coyne et al developed a condition specific ques-
tionnaire, the OAB- q.6 7 The OAB- q was developed from 
focus groups of men and women, clinician opinion and a 
thorough literature review. More recently, this OAB- q has 
been shortened to benefit patients, researchers and clini-
cians.8 The OAB- q SF contains six questions on 6- point 
Likert- type scales, with the outcomes transformed to a 
0–100 point scale in which higher scores indicate more 
severe symptoms.8 This scale demonstrated good conver-
gent validity, discriminant validity, internal reliability, 
reproducibility and responsiveness to change.8
Both IPSS and OAB- q- SF capture symptoms that are 
not by definition patient important, but rather reflect the 
conditions under study. To study if changes on a ques-
tionnaire over time are relevant for patients, the PGI- I has 
been developed using a quantitative approach.13 15
The PGI- I is a validated generic tool for assessing 
overall improvement after treatment and is answered on a 
7- point Likert- type scale, with the following options: ‘very 
much better’, ‘much better’, ‘a little better’, ‘no change’, 
‘a little worse’, ‘much worse’ or ‘very much worse’.13 15 Full 
versions of these questionnaires are presented as online 
supplementary file 1.
We sent a reminder after 2 weeks to patients who did 
not respond to follow- up requests.
Data analyses
Baseline characteristics are reported as continuous vari-
ables and summarised as mean and SD or as median 
and IQR, depending on the distribution checked by 
the Shapiro- Wilk test. These characteristics were also 
compared between men with and without completed 
follow- up data to test for selective non- response. Next, the 
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by comparing the data between the baseline and follow- up 
questionnaires. Change scores were inverted to facilitate 
intuitive interpretation, with positive scores reflecting 
symptom improvement.
Various methods exist to determine the MID of ques-
tionnaires and are typically either anchor- based or 
distribution- based.9 16–18 The latter involve evaluating 
change in the PROM with the probability that the change 
occurred by chance, sample variation or measurement 
precision; however, they do not reflect patient perspec-
tives.17 19 Thus, we used an anchor- based method,9 in 
which we compared changes in the IPSS or OAB- q SF 
(PROM) with the PGI- I (the anchor). For each PGI- I cate-
gory, we then present the mean change in scores from 
baseline to follow- up with the associated CIs. We defined 
the MID as the mean change in IPSS or OAB- q SF for the 
PGI- I category ‘a little better’, as the M in MID reflects 
the minimal change that is considered relevant. We also 
present the mean change scores for the other PGI- I 
categories.
The usefulness of anchor- based approaches depends on 
the relationship between the PROM and the anchor.20–22 
The anchor and PROM should be measuring the same 
or similar underlying constructs and should therefore be 
appreciably correlated. Correlations between question-
naire change scores and the anchor PGI- I should be obvi-
ously strong, as else these measure different concepts. 
Correlations between the anchor PGI- I and the baseline 
and follow- up questionnaire scores are performed to 
check for a possible response shift. Mostly anchor PGI- I 
scores seem correlated with follow- up scores (due to 
response shift). We therefore examined the Spearman 
correlation coefficients between the PGI- I and the IPSS 
and OAB- q SF for the baseline, follow- up and change 
data to ensure the anchor’s validity. A correlation coeffi-
cient between the symptom change scores and the PGI- I 
of ≥0.50, and an equal and opposite correlation of the 
PGI- I with the baseline score and the follow- up score, 
were considered ideal and likely to yield trustworthy MID 
estimates.20–22
To test the impact of baseline symptom severity on the 
distribution of results, a stratified analysis was performed 
for the IPSS categories ‘moderate symptoms’ and ‘severe 
symptoms’ because previous research has shown that such 
stratification has a large impact.2 No such categories have 
been defined for the OAB- q SF, so we did not perform 
a similar analysis for this questionnaire. Subgroup anal-
yses were also performed with participants who received 
their prescription from their GP, allowing us to provide 
data that focused on the primary care setting. Finally, we 
checked if the MID exceeded the measurement error.15 17 
For this, we calculated the SE of measurement (SEM) 
as follows: (SD×(1−reliability)1/2). Cronbach’s alpha was 
used as the reliability measure.23
The complete data set was used without imputing 
missing data. All analyses were performed using IBM 
SPSS V.25.0 (IBM Corp., Armonk, New York, USA), and 
we considered a p value <0.05 to be statistically significant.
Patient and public involvement
This study was performed without patient involvement. 
We did not invite patients to comment on the study design 
nor did we consult them to interpret the results. Patients 
were not invited to contribute to the writing or editing of 
this document for readability or accuracy.
ReSulTS
A total of 251 men completed the baseline question-
naires, of which 165 also completed the follow- up ques-
tionnaires. The baseline characteristics of men with and 
without follow- up data are shown in table 1, with no 
statistically significant differences found between these 
groups. Notably, 86.3% of the participants received their 
prescription from a GP and the remainder received it 
from a urologist.
There were mean improvements in the IPSS and OAB- q 
SF scores during the study of 5.8 (SD 6.7) and 11.8 points 
(SD 17.4), respectively. Between baseline and follow- up 
at 6 weeks, the mean IPSS changed from 19.1 (SD 6.8) to 
13.3 (SD 6.5) and the mean OAB- q SF score changed from 
39.7 (SD 19.2) to 27.9 (SD 16.9). The PGI- I outcomes are 
shown in table 2 and indicate that most men reported 
that they were ‘a little better’ or ‘much better’ (74.7%), 
while only 23.5% perceived no change. Only three men 
(1.8%) reported ‘worsened’ symptoms, and none of the 
participants reported ‘much worsened’ or ‘very much 
worsened’ symptoms.
Table 2 also shows the distribution of changes in the 
IPSS and OAB- q SF for each PGI- I category. The MID for 
the IPSS was 5.2 points (95% CI 3.9 to 6.4) and the PGI- I 
outcomes ‘no change’ and ‘much better’ corresponded 
to IPSS symptom changes of 3.1 points (95% CI 1.1 to 5.1) 
and 8.7 points (95% CI 6.8 to 10.7), respectively. The MID 
for the OAB- q SF was 11.0 points (95% CI 7.1 to 14.9) 
and the PGI- I outcomes ‘no change’ and ‘much better’ 
corresponded with mean improvements of 3.0 points 
(95% CI −2.3 to 8.4) and 19.1 points (95% CI 14.3 to 
24.0), respectively. For both questionnaires, the CIs of the 
MID- categories showed an overlap with the ‘no change’ 
categories.
The Spearman correlation coefficients were then calcu-
lated between the PGI- I and both the IPSS and the OAB- q 
SF. The correlation was −0.51 for the PGI- I and baseline 
IPSS, 0.43 for the PGI- I and follow- up IPSS and 0.38 for 
the PGI- I and change in IPSS. The corresponding correla-
tions for the OAB- q SF were −0.09 at baseline, 0.36 at 
follow- up and 0.42 for the change.
Subgroup analyses of data for men with a prescription 
from a GP found no relevant differences, with MID values 
of 5.4 for the IPSS and 11.2 for the OAB- q SF (table 3). 
Stratified analysis of baseline data revealed that men with 
severe symptoms had higher MID values for the IPSS, 
reaching 7.1 (95% CI 5.3 to 9.0), compared with the MID 
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Table 1 Baseline characteristics of all participants and participants who dropped out after the baseline questionnaire
Participants with completed 
follow- up
(n=165)
Drop out after baseline
(n=86) P value
Age (mean±SD) 66.7±9.7 65.4±12.1 0.42*
Prescription from GP (%) 86.3 83.2 0.55†
IPSS (mean±SD) 19.1±6.8 17.6±6.5 0.11*
IPSS categories (%) 0.12
  None/mild 3.7 6.4
  Moderate 50.9 61.5
  Severe 45.3 32.1
IPSS quality of life (median | IQR) 4.0 | 3.0–5.0 4.0 | 3.0–5.0 0.52‡
OAB- q SF (mean±SD) 39.8±19.2 40.7±18.1 0.70*
Duration of LUTS in months (median | IQR) 24.0 | 5.0–42.0 12.0 | 3.0–36.0 0.11‡
History of surgery for LUTS (%) 1.2 3.8 0.19†
*Student’s t- test.
†χ2 test.
‡Mann- Whitney U test.
GP, General practitioner; IPSS, International Prostate Symptom Score; IQR, Interquartile Range; LUTS, lower urinary tract symptoms; OAB- q 
SF, Overactive Bladder Questionnaire short form.
Table 2 Change scores for the IPSS and OAB- q SF by PGI- I outcomes
PGI- I outcome N (%) IPSS Missing OAB- q SF Missing
Very much better 6 (3.6) 13.4 (2.9 to 23.9) 1 23.8 (2.3 to 45.3) 0
Much better 50 (30.3) 8.7 (6.8 to 10.7) 2 19.1 (14.3 to 24.0) 3
A little better 68 (41.2) 5.2 (3.9 to 6.4) 3 11.0 (7.1 to 14.9) 4
No change 38 (23.0) 3.1 (1.1 to 5.1) 0 3.0 (−2.3 to 8.4) 4
A little worse 3 (1.8) −5.0 (−30.9 to 20.9) 0 −9.7 (−81.7 to 62.4) 0
Change in IPSS and OAB- q SF scores were estimated by comparing symptom scores between baseline and 6 weeks. Mean change and 
95% CIs are presented. Outcomes are inverted so that positive changes reflect symptom improvement. The PGI- I category ‘a little better’ 
reflects the MID for both questionnaires. None of the participants scored ‘much worsened’ or ‘very much worsened’ on the PGI- I.
IPSS, International Prostate Symptom Score; MID, minimal important difference; OAB- q SF, Overactive Bladder Questionnaire short form; 
PGI- I, Patient Global Impression of Improvement.
Finally, the SEM was 3.6 for the IPSS and 9.7 for the 
OAB- q SF.
DISCuSSIOn
We estimated the MID for two questionnaires that are 
often used to assess male LUTS in primary care. However, 
whereas the SEM of the IPSS was less than the 95% CI of 
the MID (5.2 points; 95% CI 3.9 to 6.4; SEM 3.6), the SEM 
of the OAB- q SF fell within the 95% CI of the MID (11 
points; 95% CI 7.1 to 14.9; SEM 9.7). Thus, we can only 
conclude that the outcomes for the IPSS were unlikely to 
have occurred because of chance or measurement impre-
cision. Given that many questionnaires have used multiple 
MID values, we were surprised to find only one previous 
estimate of the MID for the IPSS in the literature.1 2 Our 
study therefore adds relevant information in the primary 
care setting for clinicians and guideline developers.
Our results for the IPSS were different to those of the 
seminal study on this topic performed by Barry et al in 
secondary care.1 2 In that study, the MID of 3.1 points (SD 
0.27) fell within the 95% CI of the ‘no change’ group 
(consisting of men who expressed that they hadn’t expe-
rienced any change in symptoms), but outside the CI of 
the ‘a little better’ group, suggesting a likely underesti-
mation of the real value. In the current study, there was 
also some overlap between the CIs of the ‘no change’ 
and the ‘a little better’ group, though this was within a 
change of only 3.9–5.1 points. This could be explained 
by the relatively small samples in the subgroup anal-
yses. Given that treatment is typically in primary care, 
we have therefore provided additional data that is 
applicable to most men with LUTS. Nevertheless, the 
differences in outcomes compared with the study by 
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Table 3 Change scores for the IPSS and OAB- q SF by PGI- I outcomes: subgroup analysis for GP prescriptions
PGI- I outcome N (%) IPSS Missing OAB- q SF Missing
Very much better 4 (3.1) 18.0 (1.7 to 34.3) 1 30.8 (−0.9 to 62.4) 0
Much better 39 (30.2) 9.2 (7.0 to 11.5) 2 19.9 (14.8 to 24.9) 2
A little better 57 (44.2) 5.4 (4.0 to 6.7) 3 11.2 (7.0 to 15.4) 3
No change 27 (20.9) 3.1 (0.5 to 5.6) 0 3.3 (−3.4 to 9.9) 3
A little worse 2 (1.6) −8.5 (−11.6.5 to 99.5) 0 −16.5 (−353.2 to 320.2) 0
Change in IPSS and OAB- q SF scores were estimated by comparing symptom scores between baseline and 6 weeks. Mean change and 
95% CIs are presented. Outcomes are inverted so that positive changes reflect symptom improvement. The PGI- I category ‘a little better’ 
reflects the MID for both questionnaires. None of the participants scored ‘much worsened’ or ‘very much worsened’ on the PGI- I.
IPSS, International Prostate Symptom Score; MID, minimal important difference; OAB- q SF, Overactive Bladder Questionnaire short form; 
PGI- I, Patient Global Impression of Improvement.
Table 4 Change scores for the IPSS by PGI- I outcomes
PGI- I outcome
Moderate symptoms (n=88) Severe symptoms (n=73)
N (%) Change Missing N (%) Change
Very much better 3 (3.4) 6.5 (−50.7 to 63.7) 1 3 (4.1) 18 (1.7 to 34.3)
Much better 30 (34.1) 5.6 (3.7 to 7.5) 1 19 (26.0) 13.5 (10.5 to 16.5)
A little better 33 (37.5) 3.2 (1.7 to 4.8) 0 32 (43.8) 7.1 (5.3 to 9.0)
No change 19 (21.6) 1.3 (−1.7 to 4.3) 0 19 (26.0) 4.9 (2.3 to 7.6)
A little worse 3 (3.4) −5.0 (−31.0 to 20.9) 0 0 (0.0) –
These results are stratified by baseline symptom severity on the IPSS: moderate symptoms are scores of 8–19 and severe symptoms are 
scores of ≥20. Change in IPSSs were estimated by comparing symptom scores between baseline and 6 weeks. Mean change and 95% CIs 
are presented. Outcomes are inverted so that positive changes reflect symptom improvement. The PGI- I category ‘a little better’ reflects the 
MID for both questionnaires. None of the participants scored ‘much worsened’ or ‘very much worsened’ on the PGI- I.
IPSS, International Prostate Symptom Score; MID, minimal important difference; OAB- q SF, Overactive Bladder Questionnaire short form; 
PGI- I, Patient Global Impression of Improvement.
that three methodological differences account for these 
differences.
First, Barry et al compared patients between baseline 
and follow- up after 13 weeks. By contrast, the follow- up 
period in the current study was only 6 weeks. Although 
this difference of 7 weeks may have affected the ability of 
patients to recall their prior health state accurately, the 
true impact of this remains unclear. Change scores may 
also have been influenced by the natural variation that 
occurs in symptom severity over time.
Second, in the research by Barry et al, a different 
global assessment of patient improvement was used. 
This included a 5- point scale with the options ‘marked 
improvement’, ‘moderate improvement’, ‘slight improve-
ment’, ‘no improvement’ and ‘worse’ for which the exact 
question was not reported. In our study, we used a 7- point 
Likert- type scale that ranged from ‘very much better’ to 
‘very much worsened’. We considered that this difference 
probably had no more than a marginal impact given that 
the positive outcome categories were comparable in both 
studies. Notably, none of the participants in our study 
reported that the symptoms had ‘very’ or ‘very much’ 
worsened.
Third, we mainly included men from primary care, 
rather than men solely from secondary care. Although it 
is generally thought that men in primary care have fewer 
symptoms, our men tended to have more severe symp-
toms (IPSS >19) than in the study by Barry et al (45% vs 
25%). Barry et al also reported that baseline severity had 
a major impact on the MID, but when we compare their 
stratified analysis with ours, we had higher mean change 
scores for each PGI- I category. This might be explained by 
the fact that we only included men who actually used an 
alpha- blocker. In contrast to this focused approach, Barry 
et al used data for all participants in a large, randomised, 
double- blind trial of four treatment strategies for male 
LUTS. In their study, a lower MID could therefore have 
resulted from the inclusion of patients receiving placebo, 
finasteride, terazosin or combination therapy given 
that the efficacy of alpha- blockers exceeds that of both 
placebo and finasteride. The use of blinding meant that 
men who used placebo or finasteride may have overesti-
mated their subjective improvement, while alpha- blocker 
users may have underestimated their subjective improve-
ment. Given that the IPSS objectively counts symptoms, 
the placebo and finasteride users would experience a 
smaller change in the IPSS whereas the active drug users 
would experience a larger effect. Although the actual 
impact of each intervention is unknown, researchers in 
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We were unable to find any prior estimates of the MID 
for the OAB- q SF in the literature. Our finding that 11.0 
points (95% CI 7.1 to 14.9) indicates a clinically relevant 
change is therefore a novel and important finding, but 
one for which the reliability will need to be assessed in 
other studies. We recognise that alpha- blockers are not 
specifically indicated for the treatment of OAB, but we 
contend that there is a considerable overlap with LUTS 
unrelated to OAB. Indeed, guidelines suggest prescribing 
alpha- blockers for most men with LUTS who request 
active treatment. This is because these agents have a rapid 
onset of action, good efficacy, and low rate and severity of 
adverse events.3–5 We recommend further study to deter-
mine the MID in men with specific symptoms of OAB 
treated with anticholinergics or beta-3 agonists.
Some limitations need to be considered when assessing 
our results. Notably, the sample size of this study was 
small, which resulted in very low numbers of men being 
included in the PGI- I category ‘very much better’. For that 
category, the mean change scores for both questionnaires 
showed very wide CIs. The same holds for the catego-
ries linked to symptom worsening. In those categories, a 
discontinuation trial, in which men stop their treatment, 
may be more suitable for reliable estimates. The sample 
size might also explain why the CI of the MID estimate for 
the OAB- q SF included the SEM.
Another limitation is reflected by difficulties we 
encountered with some of the associations between the 
PGI- I and the two PROM questionnaires. For the IPSS, 
the follow- up IPSS and PGI- I scores correlated better than 
with IPSS change and PGI- I scores, suggesting that this 
rating only reflected the current status, which in turn, 
decreases confidence in the MID estimate. For the OAB- q 
SF, the correlation coefficient between the baseline 
OAB- q SF and PGI- I scores was opposite in magnitude to 
that for the follow- up OAB- q SF and PGI- I scores. With 
both questionnaires, the correlation coefficients for the 
change scores were lower than the threshold of 0.5 that we 
set a priori.21 High correlation coefficients are preferred 
between the anchor and the change in PROM, though 
some researchers have suggested applying lower thresh-
olds.25 Still, even the high correlation coefficients are 
insufficient to confirm that the transition rating is in fact 
measuring change as opposed to current health status.21 
Unfortunately, Barry et al did not report the correlation 
coefficients between the IPSS and the anchor,2 which is 
consistent with most other research for PROMs.26 Given 
the suboptimal relationship between the PROM and the 
anchor, we must stress that the estimates obtained for the 
MID should be interpreted with caution and should be 
confirmed in future investigations with larger samples.
In conclusion, this study is the first to define MID values 
for two important PROMs used to evaluate the effective-
ness of treatment for male LUTS in primary care. Given 
that many men are treated in primary care, MID values for 
this setting are particularly important to inform evidence- 
based decision- making and to facilitate interpretation of 
the IPSS and OAB- q SF. Moreover, we consider that this 
study emphasises the importance of the MID to individual 
patients in daily practice. We defined the MID based on 
the PGI- I outcome ‘a little better’ in the present study, but 
patients may expect ‘much better’ as an outcome when 
starting therapy. To date, most outcomes of alpha- blocker 
and other drug treatments for male LUTS have been 
expressed as the mean IPSS change scores. In the vast 
majority of studies,3 difference in IPSS changes between 
active treatment and placebo have approached, but not 
exceeded, the previously reported MID of 3.1.1 2 Applying 
a threshold for improvement of 5.2 points, as described in 
our study, may change the interpretation of those studies.
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